跳到主要內容

臺灣博碩士論文加值系統

(216.73.217.68) 您好!臺灣時間:2026/11/20 23:19
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

: 
twitterline
研究生:陳耕民
研究生(外文):CHEN, GENG-MIN
論文名稱:應用聚乙二醇-奈米鑽石複合物作為抗生素傳遞平台,於抵抗多重耐藥性細菌之研究
論文名稱(外文):Application of PEGylated Nanodiamond as Antibiotic Carrier Against Multidrug-Resistant Bacteria
指導教授:吳志哲
指導教授(外文):WU, CHIH-CHE
口試委員:吳志哲、吳立真、王亦生
口試委員(外文):WU, CHIH-CHE、WU, LI-ZHEN、WANG, YI-SHENG
口試日期:2019-07-03
學位類別:碩士
校院名稱:國立暨南國際大學
系所名稱:應用化學系
學門:自然科學學門
學類:化學學類
論文種類:學術論文
論文出版年:2019
畢業學年度:107
語文別:中文
論文頁數:60
中文關鍵詞:奈米鑽石、聚乙二醇、抗生素、多重耐藥性細菌
外文關鍵詞:Nanodiamond、Polyethylene glycol、Antibiotic、Multidrug-resistant bacteria
DOI:10.6837/ncnu201900089
相關次數:
  • 被引用被引用:0
  • 點閱點閱:215
  • 評分評分:
  • 下載下載:1
  • 收藏至我的研究室書目清單書目收藏:0
細菌對抗生素產生的耐藥性,尤其是多重藥物耐藥性 (Multidrug resistance, MDR) 已成為全球關注的醫學問題。世界衛生組織(WHO)提出了關於細菌多重耐藥性的警告,多重耐藥性細菌的出現已成為人類面臨的嚴重問題之一,因此,尋找解決方案變的重要,例如鑑定新的抗生素和奈米結構材料的有效利用。其中,奈米鑽石 (Nanodiamond,ND),具有化學穩定度高、表面容易修飾以及對生物分子有很好的吸附力等特性,已成為一種新興的奈米材料。在過去幾年中,已經有一些關於ND表面修飾的研究。ND可以用各種高分子進行修飾,例如,聚乙二醇(polyethylene glycol, PEG),已成功的與各種奈米粒子(量子點和金奈米粒子)結合,具有增強生物學的特性,高生物相容性,增強其溶解性,滲透性和穩定性,同時避免它們被免疫系統快速識別和消除,從而延長體內循環。
因此在這篇論文中,我們選用奈米鑽石-聚乙二醇複合體 (ND@PEG) 作為藥物傳遞的載體,將PEG修飾後的ND與環丙沙星 (Ciprofloxacin,CFX) 進行物理吸附後,形成一個奈米鑽石藥物複合體 (ND@PEG-CFX),用來研究對抗多重耐藥性大腸桿菌 (MDR E. coli)。實驗結果顯示,在中性水溶液中 (pH 7.0),ND@PEG表面能夠吸附約1% (w/w)的CFX藥物,並能夠緩慢釋放超過24小時。在細胞存活率的分析中,ND@PEG-CFX即使在40 (g/mL)高濃度下,細胞存活率仍達到100%,表現出優良的生物相容性。我們以共聚焦螢光顯微鏡對ND@PEG與MDR E. coli的作用位置進行分析,螢光光譜影像顯示,ND@PEG會貼附在多重耐藥性大腸桿菌細菌的表面,並引起細菌的聚集現象。在多重耐藥性大腸桿菌的抗菌實驗中,ND@PEG-CFX殺菌效果達到97.17%,遠高於單純使用等校濃度的CFX藥物效果72.27%,驗證了ND@PEG輔助的藥物傳遞機制可以更有效率地殺死多重耐藥性大腸桿菌。我們推測這顯著提高的抗菌能力歸因於奈米鑽石複合物的輔助藥物遞送特性,能使奈米鑽石藥物複合物在細菌細胞膜外持續並且緩慢釋放。奈米鑽石複合物與環丙沙星的結合不只可以延長藥物與細菌的有效作用時間,還可以繞過外排泵蛋白質對藥物的作用機制來提高奈米鑽石藥物的抗菌效力。
這些實驗結果顯示,奈米鑽石-聚乙二醇複合體作為藥物傳遞平台具有緩慢釋放藥物、對人體細胞低毒性,可以搭載環丙沙星藥物對多重耐藥性大腸細菌產生作用,繞過細菌外排泵的耐藥性機制,提高殺菌效果,在未來有機會可以應用於致病耐藥性細菌感染的臨床治療上。

Bacterial resistance to antibiotics, especially multidrug resistance (MDR), has become a global medical concern. The World Health Organization (WHO) has warned of multiple drug resistance in bacteria, and the emergence of multi-drug resistant bacteria has become one of the pressing problems facing humans. Therefore, it is important to explore alternatives such as the identification of new antibiotics and the efficient use of nanostructured materials. Among them, Nanodiamond (ND), which has high chemical stability, easy surface modification and good adsorption to biomolecules, has become a new nanomaterial. In the past few years, there have been some studies on ND surface modification. ND can be modified with various polymers, such as polyethylene glycol (PEG), which has been successfully combined with various nanoparticles (quantum dots and gold nanoparticles), has enhanced biological properties, and is highly biocompatible. It enhances their solubility, permeability, and stability while avoiding rapid recognition and elimination by the immune system, thereby prolonging circulation in the body.
Therefore, in this work, we used PEGylated nanodiamond (ND@PEG) as a drug delivery platform. After the polymer-modified nanodiamond was physically adsorbed with Ciprofloxacin (CFX), a nanodiamond-drug complex (ND@PEG-CFX) was formed to resistance MDR bacteria. The experimental results show that in a neutral aqueous solution (pH 7.0), the surface of the ND@PEG can adsorb about 1% (w/w) of ciprofloxacin and can be slowly released for more than 24 hours. In the analysis of cell viability, ND@PEG-CFX showed excellent biocompatibility when the cell viability reached 100% even at a high concentration of 40 (g/mL). In the antibacterial experiment, the bactericidal effect of ND@PEG-CFX reached 97.17%, which was greater than 72.27% of CFX alone. The results showed that MDR Escherichia coli (E. coli) were more susceptible to death by ND@PEG-CFX than the experimental control group using only ciprofloxacin alone, which confirmed that ND@PEG-assisted drug delivery mechanism can kill MDR E. coli more effectively. We speculate that this significantly improved antibacterial ability is attributed to the auxiliary drug delivery properties of the nanodiamond complex, which allows the drug to continued and slowly release outside the bacterial cell membrane. ND@PEG-CFX can not only prolong the effective time of the bacteria and can also bypass the action mechanism of the efflux pump protein to improve the antibacterial efficacy.
These results show that the ND@PEG has a slow release property as a drug delivery platform and is low-toxic to human cells. It can carry ciprofloxacin on MDR E. coli, bypassing the drug resistance mechanism of bacterial efflux pumps, enhances the bactericidal effect and has the opportunity to be applied to the clinical treatment of pathogenic drug-resistant bacterial infection in the future.

謝誌i
摘要ii
Abstract iv
目次vi
表目次ix
圖目次x
第一章 緒論 1
1.1 前言1
1.2 抗生素1
1.3 細菌表面結構之簡介2
1.3.1 抗生素耐藥性細菌3
1.4 奈米材料簡介5
1.4.1 奈米材料載體5
1.4.2 奈米鑽石載體5
1.5 奈米鑽石表面修飾5
1.6 聚乙二醇表面修飾之特性5
1.7 聚合酶連鎖反應的簡介(Polymerase chain reaction,PCR) 6
1.7.1 聚合酶連鎖反應的臨床應用6
1.7.2 即時聚合酶鏈鎖反應 (Real-time polymerase chain reaction,Real-time PCR) 6
1.7.3 實驗目的7
第二章 實驗方法8
2.1 實驗藥品8
2.2 儀器裝置9
2.3 羧基-奈米鑽石的製備17
2.3.1 7 nm奈米鑽石的表面空氣氧化處理17
2.3.2 7 nm奈米鑽石的表面酸洗處理17
2.4 聚乙二醇-奈米鑽石的製備 (ND@PEG) 18
2.5 聚乙二醇奈米鑽石-環丙沙星的製備 (ND@PEG-CFX) 18
2.6 環丙沙星之檢量線與吸附量估計19
2.7 環丙沙星之吸附比例與吸附平衡時間19
2.8 聚乙二醇奈米鑽石-環丙沙星之藥物釋放速率19
2.9 聚乙二醇奈米鑽石-環丙沙星對人體HeLa細胞之細胞毒性實驗20
2.10 細菌培養與培養基的製作 20
2.10.1 菌種來源20
2.10.2 細菌菌種20
2.10.3 TSB液態培養基20
2.10.4 TSB固態培養基 (TSB Agar) 21
2.10.5 TSB-抗生素固態培養基 (TSB- Antibiotic Agar) 21
2.10.6 野生型大腸桿菌樣品的前處理 (Wild-Type E. coli) 22
2.10.7 環丙沙星耐藥性大腸桿菌樣品的製備 (MDR E. coli) 22
2.11 環丙沙星耐藥型大腸桿菌之多重耐藥性 (Multidrug-resistant) 驗證22
2.12 透過即時PCR進行acrA和acrB表達分析 23
2.13 合成互補DNA (complementary DNA,cDNA) 24
2.14 即時定量聚合酶鏈鎖反應 (Real-time Quantitative Polymerase
Chain Reaction,Real-time-PCR) 24
2.15 野生型與耐藥型大腸桿菌之最低抑制濃度 (Minimum Inhibitory
Concentration;MIC) 24
2.16 聚乙二醇奈米鑽石-環丙沙星之抗菌能力25
2.16.1 聚乙二醇奈米鑽石-環丙沙星抗菌試劑製備25
2.16.2 聚乙二醇奈米鑽石-環丙沙星耐藥型大腸桿菌之抗菌實驗25
2.17 利用共聚焦顯微鏡觀察聚乙二醇-奈米鑽石對細菌吸附的實驗26
第三章 結果與討論27
3.1 材料性質探討27
3.1.1 聚乙二醇奈米鑽石-環丙沙星之表徵27
3.1.2 奈米藥物的界面電位與粒徑量測29
3.1.3 奈米藥物之抗生素含量30
3.1.4 環丙沙星之紫外光-可見光吸收光譜32
3.2 環丙沙星藥物自聚乙二醇奈米鑽石粒子釋放模擬(In Vitro Release Kinetics of Drugs from NPs) 35
3.3 聚乙二醇奈米鑽石之分散性實驗37
3.4 多重耐藥性大腸桿菌之培養38
3.5 聚乙二醇奈米鑽石-環丙沙星粒子與多重耐藥性大腸桿菌細菌的作用位置41
3.6 聚乙二醇奈米鑽石-環丙沙星粒子對人體HeLa細胞毒性試驗42
3.7 多重耐藥性大腸桿菌細菌的耐藥性機制43
3.8 野生型與耐藥性大腸桿菌之抗生素最低抑菌濃度 (MIC) 47
3.9 聚乙二醇奈米鑽石-環丙沙星粒子對於多重耐藥性大腸桿菌 (MDR E. coli) 之抗菌能力49
3.9.1 奈米藥物在固態培養基上之分散性與抗菌能力 (For MDR E. coli) 51
3.9.2 奈米藥物之抑菌環試驗52
3.9.3 不同藥物濃度對多重耐藥性大腸桿菌之影響53
3.10 奈米藥物與細菌細胞膜之作用55
第四章 結論 56
參考文獻57 
表目次
Table 1 Physical-chemical characterization of nanoparticles used in this study 29
Table 2 Loading capacity of ND@PEG-CFX 34
Table 3 Relative expression of acrA and acrB in mutant I (MDR E. coli + TSB) and mutant II (MDR E. coli + CFX-TSB) as determined by Real-time PCR 45
Table 4 List of real time PCR primers 45
 
圖目次
Figure 1  Antibiotics: Mechanism of action 1
Figure 2  Bacterial surface structure (A) Gram-positive bacteria and (B) Gram-negative bacteria 3
Figure 3  Resistance mechanism of antibiotic resistant bacteria 4
Figure 4 Threshold level on a qPCR amplification curve 7
Figure 5  FTIR spectra of ND,ND@PEG, and ND@PEG-CFX 28
Figure 6  TGA analysis of ND,ND@PEG and ND@PEG-CFX 31
Figure 7 Absorbance curve of CFX on PEGylated nanodiamond and free CFX (25 g/mL) 33
Figure 8 Ultraviolet-visible calibration curve of free CFX 33
Figure 9 Optimization of mixing time of ND@PEG-CFX 34
Figure 10 In vitro CFX release kinetics of ND@PEG-CFX and ND-CFX in DI water (pH 7.0) 36
Figure 11 In vitro free CFX release in DI water (pH 7.0) 36
Figure 12 Dispersions of the ND (1), and ND@PEG (2) in PBS soluiton. Setting for (A) 0 min, (B) 20 min, (C) 40 min, (D) 60 min 37
Figure 13 Survival rate of MDR E. coli in the absence or presence of ciprofloxacin
(40 ng/mL) 39
Figure 14 The photos of WT E. coli and MDR E. coli plate on different kind of
antibiotic plates 40
Figure 15 Composite fluorescence images of MDR E. coli (blue) treated ND@PEG (red) for 30 minute. Scale bars are 10 m 41
Figure 16 Cell viability assays of HeLa cells treated with ND@PEG-CFX.The experiments were repeated in triplicate 42
Figure 17 Schematic drawing of multidrug efflux system AcrAB–TolC of the
Gram-negative bacterium Escherichia coli 44
Figure 18 Amplification curve and standard curve of acrA, acrB and gapA in Wild-Type E. coli 46
Figure 19 Optical density of WT E. coli incubated at different concentration of CFX solution for 24 h 47
Figure 20 Optical density of MDR E. coli incubated at different concentration of CFX solution for 24 h 48
Figure 21 (A) The photos of MDR E. coli treated with no-drug (control), CFX and
ND@PEG-CFX in TSB broth. The bacterial survival (B) and number of colony-forming unit per mL (C) of MDR E. coli after treatment with free CFX (400 ng/mL) and ND@PEG-CFX (40 g/mL) for 1 h 50
Figure 22  Bacteria growth inhibition test of CFX and ND@PEG-CFX embedded agar plates 51
Figure 23  Digital images of the inhibition zones of three paper samples against: (a) MDR E. coli, and (b) wide type E. coli,(i) control, (ii) CFX and (iii) ND@PEG-CFX 52
Figure 24 Bacterial suspensions exposed to different ND@PEG-CFX concentrations at 37°C for 5 h 54
Figure 25  The growth curves of MDR E. coli after treatment with fee CFX (20 ng/mL, 40 ng/mL) and ND@PEG-CFX (2 g/mL), respectively 54
Figure 26  Optical microscopy (100X) of MDR E. coli after treatment with ND@PEG-CFX for (A) 30 min, and (B) 2 hrs 55

1.Taubes, G. The bacteria fight back. Science 2008, 321 (5887), 356-361.
2.Rice, L. B. Emerging Issues in the Management of Infections Caused by Multi-Drug-Resistant, Gram-Negative Bacilli. Surgical Infections 2005, 6, 37-47.
3.Antibiotic Resistance Threats in the United States, U.S. Department of Health and Human Services, U.S. Centers for Disease Control and Prevention, Washington, DC, 2013.
4.Chifiriuc, M. C.; Holban, A. M.; Curutiu, C.; Ditu, L. M.; Mihaescu, G.; Oprea, A. E.; Grumezescu, A. M.; Lazar, V. Antibiotic Drug Delivery Systems for the Intracellular Targeting of Bacterial Pathogens. INTECH 2016.
5.Scott, J. R.; Barnett, T. C. Surface proteins of gram-positive bacteria and how they get there. Annual review of microbiology 2006, 60 (1), 397-423.
6.Hajipour, M. J.; Fromm, K. M.; Ashkarran, A. A.; de Aberasturi, D. J.; de Larramendi, I. R.; Rojo, T.; Serpooshan, V.; Parak, W. J.; Mahmoudi, M. Antibacterial properties of nanoparticles. Trends in biotechnology 2012, 30 (10), 499-511.
7.Harden, V. P.; Harris, J. O. The isoelectric point of bacterial cells. Journal of Bacteriology 1953, 65 (2), 198.
8.Nordmann, P.; Dortet, L.; Poirel, L. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends in molecular medicine 2012, 18 (5), 263-72.
9.Wen, C.-Y.; Hu, J.; Zhang, Z. L.; Tian, Z. Q.; Ou, G. P.; Liao, Y. L.; Li, Y.; Xie, M.; Sun, Z. Y.; Pang, D. W. One-step sensitive detection of Salmonella typhimurium by coupling magnetic capture and fluorescence identification with functional nanospheres. Analytical chemistry 2013, 85 (2), 1223-1230.
10.Fu, C. C.; Lee, H. Y.; Chen, K.; Lim, T. S.; Wu, H. Y.; Lin, P. K.; Wei, P. K.; Tsao, P. H.; Chang, H. C.; Fann, W. Characterization and application of single fluorescent nanodiamonds as cellular biomarkers. Proceedings of the National Academy of Sciences of the United States of America 2007, 104 (3), 727-32.
11.Wang, D.; Tong, Y.; Li, Y.; Tian, Z.; Cao, R.; Yang, B. PEGylated nanodiamond for chemotherapeutic drug delivery. Diamond and Related Materials 2013, 36, 26-34.
12.Green, A. E.; Rose, P. G. Pegylated liposomal doxorubicin in ovarian cancer. International journal of nanomedicine 2006, 1 (3), 229–239.
13.Gradishar, W. J. Albumin-bound paclitaxel: a next-generation taxane. Expert Opinion. Pharmacotherapy. 2006, 7 (8), 1041-1053.
14.Moore, L. K.; Chow, E. K.; Osawa, E.; Bishop, J. M.; Ho, D., Diamond-lipid hybrids enhance chemotherapeutic tolerance and mediate tumor regression. Advanced materials 2013, 25 (26), 3532-41.
15.Toh, T. B.; Lee, D. K.; Hou, W.; Abdullah, L. N.; Nguyen, J.; Ho, D.; Chow, E. K. Nanodiamond-mitoxantrone complexes enhance drug retention in chemoresistant breast cancer cells. Molecular pharmaceutics 2014, 11 (8), 2683-91.
16.Kim, H. J.; Zhang, K.; Moore, L., and Ho, D., Diamond Nanogel-Embedded Contact Lenses Mediate Lysozyme-Dependent Therapeutic Release. ACS nano 2014, 8 (3), 2998–3005.
17. Martin, R.; Alvaro, M.; Herance, J. R.; Garcia, H., Fenton-Treated Functionalized Diamond Nanoparticles as Gene Delivery System. ACS Nano 2010, 4 (1), 65-74.
18. Bhattacharjee, B.; Ganguli, D.; Chaudhuri, S. Luminescent CdS Nanoparticles Embedded in Polyethylene Glycol (PEG 300) Matrix Thin Film. J. Nanopart. Res. 2002, 4 (3), 225-230.
19.Lee, J. W.; Kim, S. M.; Jung, J. Y.; Oh, B. S.; Kim, I. S.; Hong, S. K. Analysis of Total Bacteria, Enteric Members of γ-proteobacteria and Microbial Communities in Seawater as Indirect Indicators for Quantifying Biofouling. Environmental Engineering Research 2009, 14 (1), 19-25.
20.Wang, D.; Tong, Y.; Li, Y.; Tian, Z.; Cao, R.; Yang, B. PEGylated nanodiamond for chemotherapeutic drug delivery. Diamond and Related Materials 2013, 36, 26-34.
21. Xiong, Z. C.; Yang, Z. Y.; Zhu, Y. J.; Chen, F. F.; Zhang, Y. G.; Yang, R. L. Ultralong Hydroxyapatite Nanowires-Based Paper Co-Loaded with Silver Nanoparticles and Antibiotic for Long-Term Antibacterial Benefit. ACS Appl Mater Interfaces 2017, 9 (27), 22212-22222.
22.Zhang, X.; Fu, C.; Feng, L.; Ji, Y.; Tao, L.; Huang, Q.; Li, S.; Wei, Y. PEGylation and polyPEGylation of nanodiamond. Polymer 2012, 53 (15), 3178-3184.
23.Zhang, X.; Hu, W.; Li, J.; Tao, L.; Wei, Y. A comparative study of cellular uptake and cytotoxicity of multi-walled carbon nanotubes, graphene oxide, and nanodiamond. Toxicology Research 2012, 1 (1), 62.
24. Li, H. C.; Hsieh, F. J.; Chen, C. P.; Chang, M. Y.; Hsieh, P. C. H.; Chen, C. C.; Hung, S. U.; Wu, C. C.; Chang, H. C. The hemocompatibility of oxidized diamond nanocrystals for biomedical applications. Scientific Reports. 2013, 3, 3044.
25.Jaktaji, R. P.; Mohiti, E. Study of mutations in the DNA gyrase gyrA gene of Escherichia coli. Iran. J. Pharm. Res. 2010, 9 (1), 43-48.
26.Burrows, G. E.; Morton R. J.; Fales, W. H. Microdilution antimicrobial susceptibilities of selected gram-negative veterinary bacterial isolates. 1993, 541-54.
27.Jaktaji, R. P.; Jazayeri, N. Expression of acrA and acrB Genes in Esherichia coli Mutants with or without marR or acrR Mutations. Iranian Journal of Basic Medical Sciences. 2013, 16 (12), 1254-1258.
28.Pos, K. M. Trinity revealed: Stoichiometric complex assembly of a bacterial multidrug efflux pump. PNAS 2009, 106, 6893– 6894.
29.Andrews, J. M. Determination of minimum inhibitory concentrations. Journal of Antimicrobial Chemotherapy 2001, 48, 5–16.
30.Salmon, S. A.; Watts, J. L., Minimum inhibitory concentration determinations for various antimicrobial agents against 1570 bacterial isolates from turkey poults. Avian Dis 2000, 44 (1), 85-98.
31.Maier, R. M. Bacterial Growth.In Environmental Microbiology; Raina, M. Maier.; Ian, L. Pepper.; Charles P. Gerba Eds, 2009; pp 37-54.
32. Fu, C. C.; Lee, H. Y.; Chen, K.; Lim, T. S.; Wu, H. Y.; Lin, P. K.; Wei, P. K.; Tsao, P. H.; Chang, H. C.; Fann, W. Characterization and application of single fluorescent nanodiamonds as cellular biomarkers. Proceedings of the National Academy of Sciences 2007, 104 (3), 727-732.
33.Yu, Y.; Yang, X.; Liu, M.; Nishikawa, M.; Tei, T.; Miyako, E. Amphipathic Nanodiamond Supraparticles for Anticancer Drug Loading and Delivery. ACS Appl. Mater. Interfaces 2019, 11 (21), 18978-18987.
34. Pfaffl, M. W.; Horgan, G. W.; Dempfle, L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002, 30 (9), e36/1-e36/10.
35. Xue, W.; Liu, Y.; Zhang, N.; Yao, Y.; Ma, P.; Wen, H.; Huang, S.; Luo, Y.; Fan, H. Effects of core size and PEG coating layer of iron oxide nanoparticles on the distribution and metabolism in mice. Int. J. Nanomed. 2018, 13, 5719-5731.
36. Dash, S.; Murthy, P. N.; Nath, L.; Chowdhury, P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol. Pharm. 2010, 67 (3), 217-223.

QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top